6:12 PM
 | 
Sep 08, 2015
 |  BC Extra  |  Clinical News

Breo Ellipta misses in Phase III SUMMIT study

Theravance Inc. (NASDAQ:THRX) tumbled $2.43 (15%) to $13.56 on Tuesday after Breo Ellipta fluticasone furoate/vilanterol failed to significantly improve survival in patients with chronic obstructive pulmonary disease (COPD) and a history or increased risk of cardiovascular disease in a Phase III study....

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >